cPass

cPass™

cPass™ is the first-and-only FDA-authorised test for neutralising antibodies against SARS-CoV-2 (under EUA). It delivers reliable data to help estimate individual immunity against SARS-CoV-2. 

cPass™ Technology

cPass™ and cPass Express directly measure neutralising antibodies (NAb), a type of antibody produced against SARS-CoV-2 after infection and vaccination. Neutralising antibodies directly block the SARS-CoV-2 virus from entering human cells and causing an infection, making them an important biomarker for protective immunity.


The NAb test is quick, taking only 60 minutes to get the quantitative results (pathology lab) or 15 minutes to get a qualitative result (point of care) requiring only a finger prick to get one drop of blood, and inexpensive compared to personal and societal costs of COVID-19.

How cPass™ Works

The SARS-CoV-2 virus invades your cells by attaching its spike protein to the cellular ACE2 receptor much like the interaction of a “lock and key”. Once inside, the virus takes over cells and forces them to produce more replicates of the virus, causing COVID-19 infection.


Neutralising antibodies (NAb) block this interaction by obstructing the “lock and key” mechanism, effectively stopping the virus from entering cells. This makes NAb an important biomarker of immunity. Because NAb levels vary between individuals, measuring them can offer valuable insights into COVID-19 immunity.

What’s the advantage of measuring levels of immunity to COVID-19?


  1. Everyone’s immune system is different. cPass™ can measure neutralising antibody levels after vaccinations. This could help estimate our protective immunity and help understand risk levels.
  2. Vaccines come in many forms. Antibody responses vary depending on the vaccine we receive. No matter the vaccine or its mechanism of action, cPass™ can measure neutralising antibodies.
  3. Monitor antibody levels over time - it is possible that our neutralising antibody levels decrease over time. Measuring NAb with cPass™ will let us know how long immunity lasts.

cPass™ Technology Now Available in Australia

The cPass™ technology has obtained authorisation in the USA, EU, Singapore, Philippines, Indonesia and other nations, and is now available in Australia for research use only. 

Contact Us Today

Have a question? We’re here to help. Send us a message and we’ll be in touch.

Share by: